RISE UP: Studying whether an investigational drug can increase hemoglobin and reduce pain crises

The RISE UP Study is seeking to determine if an investigational molecule called mitapivat has the potential to improve the health of red blood cells in individuals living with sickle cell disease by improving the energy and reduce sickling of red blood cells.

Locations

12 United States sites

4 Belgium sites

3 France sites

3 Israel sites

2 Lebanon sites

1 Netherlands site

1 Italy site

Age

> 16 Years

Genotypes

SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia

Phase

2

LEARN MORE
THRIVE-132: Therapy for Reduction in VOC Readmissions with Inclacumab

The THRIVE-132 study is determining the safety and efficacy of a single dose of inclacumab, an investigational therapy, as a possible treatment to prevent readmission to the hospital for a vaso-occlusive crises (VOCs) in individuals with sickle cell disease.

Locations

6 United States sites

3 Turkey sites

2 Lebanon sites

1 Italy site

1 Kenya site

1 Omanc site

Age

> 12 Years

Genotypes

All types of SCD

Phase

3

LEARN MORE
An Electronic Patient Reported Pain Assessment in Sickle Cell

“The Electronic Patient Reported Pain Assessment in Sickle Cell” study aims to gather insights into painful crises in people living with sickle cell disease.

Locations

1 site

Age

> 18 Years

Genotypes

SCD type SS, SCD type Sβ0 thalassemia

Phase

N/A

LEARN MORE
Hibiscus Study: An oral investigational medication for SCD

The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.

Locations

1 United States site

1 Europe site

1 Canada site

Age

12 - 65 Years

Genotypes

All types of SCD

Phase

2/3

LEARN MORE
THRIVE-131: A study to potentially reduce VOCs in sickle cell

The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.

Locations

14 USA sites

4 Kenya sites

3 France sites

3 Italy sites

3 Turkey sites

2 Lebanon sites

1 Brazil site

1 Germany site

1 Saudi Arabia site

1 Oman site

1 Tanzania site

1 United Kingdom site

Age

> 12 Years

Genotypes

SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia

Phase

3

LEARN MORE
CaRISMA Study: An alternative way to manage sickle cell disease

To identify treatments that do not rely only on opioids or other medications.

Locations

1 United States site

Age

> 18 Years

Genotypes

All types of SCD

Phase

N/A

LEARN MORE